Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma

Abstract

The objective of this study was to investigate the effect of hyperprolactinemia and high levels of insulin-like growth factor-I (IGF-I) on bone resorption and their relation with receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) in patients with prolactinoma and acromegaly. Thirty-one patients with acromegaly, 28 patients with prolactinoma, and 33 healthy individuals were included in the study. Serum concentrations of RANKL, OPG, bone alkaline phosphatase (bone ALP), osteocalcin (OC), C-terminal telopeptide of type 1 collagen (CTX), procollagen type 1 N-terminal propeptide (P1NP) and urine deoxypyridinoline (DPD) levels were detected and bone mineral density (BMD) was measured. Groups were not statistically different from each other with regard to serum levels of RANKL and OPG. The RANKL/OPG ratio was higher in the prolactinoma group than in the control group (p=0.046). A positive correlation between OPG and increasing age was detected in both the prolactinoma and control groups (r=0.524, p=0.004 and r=0.380, p=0.029, respectively). An inverse correlation was observed between IGF-I and OPG after excluding age in the prolactinoma group (r=–0.412, p=0.046). OC and bone ALP were negatively associated with RANKL in the acromegaly group (r=–0.384, p=0.036 and r=–0.528, p=0.003, respectively). There was an inverse correlation between OPG and BMD at the femoral neck in the acromegaly group (r=–0.422, p=0.02). The effect of IGF-I on bone remodeling may be partly mediated by RANKL and OPG. The RANKL/OPG ratio plays an important role in prolactinoma. A positive correlation of OPG with age and an inverse correlation with IGF-I favor the compensatory response of OPG against bone loss in the aging skeleton.

Key words

insulin-like growth factor-I - bone - osteoprotegerin - prolactinoma - RANKL

• References

• 1 Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9 (Suppl. 01) S1
• 2 Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-253
• 3 Suda T, Takahashi N, Udagawa N, Jimi E, Gillepsie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357
• 4 Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem 2009; 107: 677-685
• 5 Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. J of Clin Endocrinol and Metab 1993; 76: 1452-1457
• 6 Ueland T. Bone metabolism in relation to alterations in systemic growth hormone. Growth Horm IGF Res 2004; 14: 404-417
• 7 Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, Rosen CJ. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002; 87: 4273-4279
• 8 Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, Krishnamra N. Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int 2008; 32: 1126-1135
• 9 Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, Zhang LZ, Xu MY, Chen JL. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. Osteoporos Int 2008; 19: 221-226
• 10 Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu OC, Ritchie J, Ioachimescu AGJ. Calcium and Bone Turnover Markers in Acromegaly: A Prospective. Controlled Study. Clin Endocrinol Metab 2017; 102: 2416-2424
• 11 Quigley R, Baum M. Effecfts of growth hormone and insulin-like growth factor 1 on rabbit proximal convoluted tubule transport. J Clin Invest 1991; 88: 368-374
• 12 Stilgren LS, Rettmer E, Eriksen EF, Hegedüs L, Beck-Nielsen H, Abrahamsen B. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 2004; 35: 256-265
• 13 Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, Teerapornpuntakit J, Suthiphongchai T, Krishnamra N. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 2008; 42: 535-546
• 14 Arslan MS, Sahin M, Karakose M, Tutal E, Topaloglu O, Ucan B, Demirci T, Caliskan M, Ozdemir S, Ozbek M, Cakal E. Serum levels of fibroblast growth factor-23, osteoprotegerin, and receptor activator of nuclear factor kappa b ligand in patients with prolactinoma. Endocr Pract 2017; 23: 266-370
• 15 Tenta R, Panagiotakos DB, Fragopoulou E, Nomikos T, Pitsavos C, Chrysohoou C, Antonopoulou S, Stefanadis C. Osteoprotegerin and nuclear factor-kappaB ligand are associated with leptin and adiponectin levels, in apparently healthy women. J Musculoskelet Neuronal Interact 2010; 10: 174-179
• 16 Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ. One year of transgenicoverexpression of osteoprotegerin in rats suppressed boneresorption and increased vertebral bone volume, density, and strength. J Bone Miner Res 2009; 24: 1234-1246
• 17 Jørgensen L, Vik A, Emaus N, Brox J, Hansen JB, Mathiesen E, Vestergaard P. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study. Osteoporos Int 2010; 21: 931-938
• 18 Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473: 139-146